(HealthDay News) — Islet transplantation seems safe and efficient for restoring glycemic control in type 1 diabetes, according to research published online in Diabetes Care.
Sandrine Lablanche, M.D., from Grenoble University Hospital in France, and colleagues conducted a retrospective analysis to describe 5-year outcomes for subjects enrolled in the GRAGIL-1c and GRAGIL-2 islet transplantation trials. Between September 2003 and April 2010, 44 patients received islet transplantation (24 islet transplantation alone [ITA] and 20 islet after kidney [IAK] transplantation).
The researchers found that 34 and 10 patients completed 5-year and 4-year follow-up, respectively. At 1,4 and 5 years post-transplantation, 83, 67, and 58% of ITA recipients and 80, 70, and 60% of IAK transplant recipients, respectively, achieved a hemoglobin A1c level below 7% and were free from severe hypoglycemia.
At the preinfusion stage, none of the ITA recipients and 10% of the IAK transplant recipients met this composite criterion. During the entire follow-up period, 75% of participants experienced insulin independence, with a median duration of insulin independence of 19.25 months. At least 1 adverse event was exhibited by 66% of recipients; 33% of events were possibly related to immunosuppression.
“Islet transplantation was safe and efficient in restoring good and lasting glycemic control, and to prevent severe hypoglycemia in patients with type 1 diabetes,” the authors write.